Dr. Reddy's Laboratories Reports Q3FY26 Results with 4.4% Revenue Growth
Dr. Reddy's Laboratories reported Q3FY26 consolidated revenues of ₹87,268 million, up 4.4% YoY, with net profit of ₹12,098 million. Growth was driven by branded businesses and favorable forex, offsetting lower Lenalidomide sales. The company achieved several strategic milestones including collaboration with Immutep and launch of Hevaxin® vaccine, while managing the impact of India's New Labour Codes implementation.
*this image is generated using AI for illustrative purposes only.
Dr. Reddy's Laboratories Limited announced its consolidated financial results for the quarter and nine months ended December 31, 2025, demonstrating resilient performance amid challenging market conditions. The pharmaceutical giant reported consolidated revenues of ₹87,268 million for Q3FY26, marking a 4.4% year-over-year growth, though declining 0.9% quarter-over-quarter.
Financial Performance Overview
The company's financial metrics for Q3FY26 reflect a mixed performance across key indicators:
| Metric: | Q3FY26 | Q3FY25 | YoY Change |
|---|---|---|---|
| Revenue: | ₹87,268 million | ₹83,586 million | +4.4% |
| Gross Profit: | ₹46,806 million | ₹49,052 million | -4.6% |
| Net Profit (Equity Holders): | ₹12,098 million | ₹14,133 million | -14.4% |
| Diluted EPS: | ₹14.52 | ₹16.94 | -14.3% |
For the nine-month period ended December 31, 2025, the company achieved revenues of ₹260,771 million, representing an 8.4% increase compared to ₹240,475 million in the corresponding period of the previous year. Net profit attributable to equity holders for nine months stood at ₹40,649 million, remaining relatively flat at 0.1% growth year-over-year.
Segment-wise Performance
The Global Generics segment remained the primary revenue driver, contributing ₹79,113 million in Q3FY26, a 7% increase year-over-year. This segment includes operations across North America, Europe, India, and Emerging Markets, with varying performance across regions.
| Segment: | Q3FY26 Revenue | YoY Growth | Nine-Month Revenue |
|---|---|---|---|
| Global Generics: | ₹79,113 million | +7% | ₹233,231 million |
| PSAI: | ₹8,018 million | -2% | ₹25,649 million |
| Others: | ₹137 million | -92% | ₹1,891 million |
North America revenues declined 12% year-over-year to ₹29,644 million, primarily due to lower Lenalidomide sales and price erosion in key products. However, Europe showed strong growth of 20% year-over-year, reaching ₹14,476 million, driven by new generic product launches and growth in the Nicotine Replacement Therapy (NRT) portfolio.
Operational Highlights and Strategic Developments
During Q3FY26, Dr. Reddy's Laboratories achieved several significant milestones that strengthen its market position. The company entered into a strategic collaboration with Immutep for commercialization of Eftilagimod Alfa, a novel immunotherapy oncology drug, with an upfront payment of US$20 million and potential milestones of up to US$349.5 million.
The company launched Hevaxin®, a novel recombinant vaccine for Hepatitis-E virus prevention in India, and received marketing authorization for Semaglutide injection from the Drugs Controller General of India. Additionally, 85% integration of the acquired Consumer Healthcare business in NRT was completed by December 2025.
Financial Impact of Regulatory Changes
A significant factor affecting the quarter's performance was the implementation of India's New Labour Codes, effective November 21, 2025. The company recognized an incremental cost of ₹1,170 million towards employee benefits during Q3FY26 due to changes in wage definitions and employee benefit obligations under these new regulations.
Profitability and Margin Analysis
Gross margin for Q3FY26 stood at 53.6%, declining 505 basis points year-over-year, primarily due to reduced Lenalidomide sales, price erosion in generics businesses, and the one-time provision related to new Labour Codes. Excluding the one-off provision, gross margin would have been 54.1% of revenues.
| Profitability Metric: | Q3FY26 | Q3FY25 | Change |
|---|---|---|---|
| Gross Margin: | 53.6% | 58.7% | -505 bps |
| EBITDA Margin: | 23.5% | 27.5% | -400 bps |
| PBT Margin: | 17.7% | 22.4% | -470 bps |
EBITDA for the quarter was ₹20,493 million, representing 23.5% of revenues, compared to 27.5% in the corresponding quarter of the previous year. The company maintained its focus on disciplined execution of strategic priorities including base business growth, pipeline advancement, and operational efficiencies.
Outlook and Management Commentary
Co-Chairman & Managing Director G V Prasad commented on the results, stating that growth in Q3FY26 was supported by continued momentum in branded businesses, aided by favorable forex movements, thus offsetting the impact of lower Lenalidomide sales. The company continues to focus on disciplined execution of strategic priorities to create long-term value for stakeholders.
The company's strong balance sheet position is reflected in its net cash surplus of ₹30.7 billion as of December 31, 2025, with a negative net debt to equity ratio of (0.08), indicating a robust financial position for future growth investments and strategic initiatives.
Source:
Historical Stock Returns for Dr Reddys Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.50% | -1.35% | -3.66% | -3.73% | +4.07% | +44.04% |
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
